BACKGROUND & AIMS: Epstein-Barr virus (EBV) has been causally associated with cancer; some gastric carcinomas have a monoclonal EBV genome in every cancer cell, indicating that they arose from a single infected progenitor cell. However, the proportion of EBV-positive gastric carcinomas is uncertain, and the etiologic significance is unknown. METHODS: We conducted a meta-analysis of 70 studies including 15,952 cases of gastric cancer assessed by in situ hybridization for EBV-encoded small RNA. RESULTS: The pooled prevalence estimate of EBV positivity was 8.7% (95% confidence interval [CI]: 7.5%-10.0%) overall, with a 2-fold difference by sex: 11.1% (95% CI: 8.7%-14.1%) of gastric cancer cases in males vs 5.2% (95% CI: 3.6%-7.4%) of cases in females. Tumors arising in the gastric cardia (13.6%) or corpus (13.1%) were more than twice as likely to be EBV-positive as those in the antrum (5.2%; P < .01 for both comparisons). EBV prevalence was 4 times higher (35.1%) for tumors in postsurgical gastric stump/remnants. Over 90% of lymphoepithelioma-like carcinomas were EBV positive, but only 15 studies reported any cases of this type; prevalence did not significantly differ between the more common diffuse (9.5%) [corrected] and intestinal (7.6%) [corrected] histologies. EBV prevalence was similar in cases from Asia (8.3%), Europe (9.2%), and the Americas (9.9%). CONCLUSIONS: EBV-positive gastric cancers greatly differ from other gastric carcinomas based on sex, anatomic subsite, and surgically disrupted anatomy, indicating that it is a distinct etiologic entity. Epidemiologic studies comparing EBV-positive and -negative gastric cancers are warranted to investigate EBV's role in gastric carcinogenesis.
BACKGROUND & AIMS:Epstein-Barr virus (EBV) has been causally associated with cancer; some gastric carcinomas have a monoclonal EBV genome in every cancer cell, indicating that they arose from a single infected progenitor cell. However, the proportion of EBV-positive gastric carcinomas is uncertain, and the etiologic significance is unknown. METHODS: We conducted a meta-analysis of 70 studies including 15,952 cases of gastric cancer assessed by in situ hybridization for EBV-encoded small RNA. RESULTS: The pooled prevalence estimate of EBV positivity was 8.7% (95% confidence interval [CI]: 7.5%-10.0%) overall, with a 2-fold difference by sex: 11.1% (95% CI: 8.7%-14.1%) of gastric cancer cases in males vs 5.2% (95% CI: 3.6%-7.4%) of cases in females. Tumors arising in the gastric cardia (13.6%) or corpus (13.1%) were more than twice as likely to be EBV-positive as those in the antrum (5.2%; P < .01 for both comparisons). EBV prevalence was 4 times higher (35.1%) for tumors in postsurgical gastric stump/remnants. Over 90% of lymphoepithelioma-like carcinomas were EBV positive, but only 15 studies reported any cases of this type; prevalence did not significantly differ between the more common diffuse (9.5%) [corrected] and intestinal (7.6%) [corrected] histologies. EBV prevalence was similar in cases from Asia (8.3%), Europe (9.2%), and the Americas (9.9%). CONCLUSIONS:EBV-positive gastric cancers greatly differ from other gastric carcinomas based on sex, anatomic subsite, and surgically disrupted anatomy, indicating that it is a distinct etiologic entity. Epidemiologic studies comparing EBV-positive and -negative gastric cancers are warranted to investigate EBV's role in gastric carcinogenesis.
Authors: Svein Hansen; Stein Emil Vollset; Mohammad H Derakhshan; Valerie Fyfe; Kjetil K Melby; Steinar Aase; Egil Jellum; Kenneth E L McColl Journal: Gut Date: 2007-02-22 Impact factor: 23.059
Authors: C Koriyama; S Akiba; K Iriya; T Yamaguti; G S Hamada; T Itoh; Y Eizuru; T Aikou; S Watanabe; S Tsugane; M Tokunaga Journal: Jpn J Cancer Res Date: 2001-09
Authors: Sang Won Kim; Hyeong Cheol Shin; Il Young Kim; Chang Jin Kim; Ji-Hye Lee; Chang Kyun Lee; Dong Jun Jeong Journal: Korean J Radiol Date: 2010-10-29 Impact factor: 3.500
Authors: Steven B Maron; Leah M Chase; Samantha Lomnicki; Sara Kochanny; Kelly L Moore; Smita S Joshi; Stacie Landron; Julie Johnson; Lesli A Kiedrowski; Rebecca J Nagy; Richard B Lanman; Seung Tae Kim; Jeeyun Lee; Daniel V T Catenacci Journal: Clin Cancer Res Date: 2019-08-19 Impact factor: 12.531
Authors: Patricia Bonequi; Fernando Meneses-González; Pelayo Correa; Charles S Rabkin; M Constanza Camargo Journal: Cancer Causes Control Date: 2012-12-07 Impact factor: 2.506
Authors: M Constanza Camargo; Woo-Ho Kim; Anna Maria Chiaravalli; Kyoung-Mee Kim; Alejandro H Corvalan; Keitaro Matsuo; Jun Yu; Joseph J Y Sung; Roberto Herrera-Goepfert; Fernando Meneses-Gonzalez; Yuko Kijima; Shoji Natsugoe; Linda M Liao; Jolanta Lissowska; Sung Kim; Nan Hu; Carlos A Gonzalez; Yashushi Yatabe; Chihaya Koriyama; Stephen M Hewitt; Suminori Akiba; Margaret L Gulley; Philip R Taylor; Charles S Rabkin Journal: Gut Date: 2013-04-12 Impact factor: 23.059
Authors: M Constanza Camargo; Kyoung-Mee Kim; Keitaro Matsuo; Javier Torres; Linda M Liao; Douglas R Morgan; Angelika Michel; Tim Waterboer; Jovanny Zabaleta; Ricardo L Dominguez; Yasushi Yatabe; Sung Kim; Erick R Rocha-Guevara; Jolanta Lissowska; Michael Pawlita; Charles S Rabkin Journal: Helicobacter Date: 2015-08-07 Impact factor: 5.753